• MirthfulAlembic@lemmy.world
    link
    fedilink
    English
    arrow-up
    19
    ·
    7 months ago

    Two points about R&D costs:

    First, they aren’t just trying to make up what they spent on this treatment, but others that failed during research/trials. There’s a lot of them the general public will never hear about, and pharmas generally don’t like to bring attention to their failures. Part of that is many shareholders are morons who don’t understand how science works.

    Second, the costs can get fuzzier for larger companies who in-house much of the R&D process, since the costs get shared among many programs. Properly attributing spend in that case can be a serious challenge.

    All that said, they’ve clearly seen an opportunity to rake it in with this trendy drug and are charging way more than they need to.